Speaker illustration

Doctor Serenella Castelvecchio

IRCCS San Donato Polyclinic, San Donato Milanese (Italy)

Dr. Serenella Castelvecchio is a cardiologist, specialized in non-invasive cardiovascular imaging, currently working at the IRCCS Policlinico San Donato (Milan, Italy), where she is the director of the Echocardiographic LAB & Follow-Up for Adult cardiac disease. The main field of interest is ischemic heart disease, with special attention for post-infarct remodeling of the left ventricle and surgical treatment of ischemic heart failure on an ischemic basis, with attention, in recent years, to the female population. She is involved in the institutional SCORE group for Surgical and Clinical Outcome Research. She is a member of expert associations such as the Italian Society of Cardiology (SIC), the Italian Federation of Cardiology (FIC), the European Society of Cardiology (ESC), the Heart Failure Association and the Mayo Alumni Association.

Identifying lifestyle patterns and awareness of cardiovascular disease among women in lombardy-italy: insights from the a call for women project

Event: ESC Preventive Cardiology 2024

Topic: Epidemiology

Session: Improving adherence, health awareness and health behaviour (1)

Thumbnail

The value of 3D-speckle tracking longitudinal strain for the assessment of left ventricular function recovery in ischemic heart failure patients undergoing surgical remodeling:the RECOVERY-IN study

Event: ESC Congress 2020

Topic: 3D Echocardiography

Session: Novel Technological Approaches in Echocardiography: What Do They Provide?

Thumbnail

Surgical treatment of ischemic heart failure in men and women: a large single center comparison

Event: ESC Congress 2019

Topic: Coronary Arteries

Session: Surgery

Thumbnail

Serial changes in N-terminal pro-brain natriuretic peptde in heart failure patients after surgical ventricular reconstruction: the biomarker plus study

Event: HEART FAILURE 2016

Topic: Natriuretic peptides

Session: Biomarkers

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb